ASCO 2017: Oral chemotherapy extends survival by more than a year in biliary tract cancer

A phase III randomised clinical trial of 447 patients with biliary tract cancers (BTCs, cancers of the bile duct and gallbladder) showed that giving capecitabine after surgery extends survival by a median of 15 months compared to surgery alone. The...

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2rsEffh
via IFTTT